Compare Nomura Holdings Inc (NMR) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs BIO-TECHNE Corp — how do they compare? Nomura Holdings Inc trades at $9.49 (market cap $28.05B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Nomura Holdings Inc is far larger — about 2.5× BIO-TECHNE Corp's market cap, and Nomura Holdings Inc pays the higher dividend (3.4%). Which is the better fit depends on your goals — on Pluang, investors hold Nomura Holdings Inc for 55 Days and BIO-TECHNE Corp for 63 Days on average.
| NMR | TECH | |
|---|---|---|
Market Cap | $28.05B | $11.37B |
Volume | 729,574 | 3,153,511 |
Sector | Financials | Health |
52-Week High | $10.86 | $72.61 |
52-Week Low | $6.73 | $43.31 |
Typical Hold Time | 55 Days | 63 Days |
Enterprise Value | $38.55T | $11.40B |
Dividend Yield | 3.4% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $9.54, down 2.45% today, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with revenue growth from $1.38T in 2024 to $1.66T in 2025 and net income surging to $340.74B. Valuation metrics appear attractive with P/E of 11.29 and P/B of 1.15, while analyst consensus leans toward Hold (66.67%) with some positive momentum coverage from Zacks.
The outlook presents a mixed picture - strong profitability and reasonable valuation support upside potential, but negative operating cash flows and increasing debt-to-asset ratios pose significant risks. Recent technical weakness suggests near-term pressure, though fundamental strength could drive recovery if earnings momentum continues.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
